Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer-Reference-Cited by-同舟云学术

Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer

Published:2016-08 Issue:1 Volume:6 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Jin Ying,Chen Ming,Yu Xinmin

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep31636.pdf

Reference35 articles.

1. Ge, L. & Shi, R. Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. International journal of clinical and experimental medicine 8, 10330–10339 (2015).

2. Russo, A. et al. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget 6, 26814–26825, 10.18632/oncotarget.4254 (2015).

3. Fukuoka, M. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29, 2866–2874, 10.1200/JCO.2010.33.4235 (2011).

4. Han, J. Y. et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30, 1122–1128, 10.1200/JCO.2011.36.8456 (2012).

5. Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet. Oncology 12, 735–742, 10.1016/S1470-2045(11)70184-X (2011).

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors;Translational Lung Cancer Research;2023-09

2. An association of epidermal growth factor receptor mutation subtypes with prognostic prediction and site-specific recurrence in advanced stage lung cancer patients;Molecular Biology Reports;2023-04-26

3. The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer;Cureus;2023-04-24

4. E3 ligase ligand optimization of Clinical PROTACs;Frontiers in Chemistry;2023-01-17

5. Clinical and Radiological Characteristics to Differentiate Between EGFR Exon 21 and Exon 19 Mutations in Patients With Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis;Cureus;2022-05-29